BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.44 (+21.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BIOCRYST PHARMACEUTICALS INC grew revenue 68.7% to $940.61M over the twelve months to Jun 30, 2026. Operating income fell 677.8% to -$313.16M, moving the operating margin from 9.7% to -33.3%. Free cash flow was $373.38M, up 2269.0% from a year earlier.
Revenue
$940.61M
+68.7% vs. a year earlier
Operating income
-$313.16M
-677.8% vs. a year earlier
Free cash flow
$373.38M
+2269.0% vs. a year earlier
EPS, diluted
-$1.50
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.14B
- P/E ratio
- –
- Price to sales
- 2.27
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 17.45%
Fundamentals
- Revenue
- $940.61M
- Net income
- -$384.67M
- EPS, diluted
- -$1.50
- Free cash flow
- $373.38M
- Book value per share
- -$1.71
- Diluted shares
- 265M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$940.61M+68.7% YoY
Gross profit
$919.69M+70.0% YoY
Operating income
-$313.16M-677.8% YoY
Net income
-$384.67M
EPS, diluted
-$1.50
Free cash flow
$373.38M+2269.0% YoY
Reported periodTrailing twelve months